Malignant Breast Cancer, Benign Breast Lesions Clinical Trial
Official title:
Breast Cancer- Early Detection of Cancer Disease and Pre-Cancer Disease, and in Women That Are at High Risk for Developing Breast Cancer by Identifying Lymphocytes Previously Exposed to Specific Cancer Antigen.
In our previous research, we have shown that women that have breast cancer have a population
of lymphocytes that recognizes specific antigen and there cytoplasmic matrix goes through
physical change a short time after exposure in vitro to the same antigen. This change can be
measured by polarization changes of fluorescent light emitted by FDA (fluorescein diacetate)
labeled cells. Further test that we performed showed that those differences are also shown
in a benign situation that known as indicator for a high risk for developing breast cancer
within 10-15 years. The incidence of the expression of these lymphocytes correlates with the
histopathological picture as it is related in high risk for the developing the disease.
In this work we will expand the scope of the procedure to early detection of the cancerous
process in breast lesions by Fitzgibbon's risk categories for the development invasive
carcinoma of the breast. In the proposed work we intend to use specific antigen MUC1 for
breast cancer. This study is a continuation of our published work in the "The Breast "
n/a
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional